DigiCon

@csrf

@if (isset(session()->get('doctor')['vCentralCode']))

Back

@else

@endif

Survey Questionnaire Form

Doctor's details

@if (isset(session()->get('doctor')['vCentralCode']))

Name of Doctor *

@else

Name of Doctor *

@endif

Age *

Gender *

Male Female

Doctor’s Degree *

Specialty *

City *

Predominant type of practice*

Multi-specialty hospital

Clinic/ nursing home

Government hospital/ medical college

Mixed

Questionnaire

In your clinical practice what proportion of patients present with Type 2 Diabetes Mellitus? *

<10%

10-<25%

25-50%

>50%

In your practice how many new cases of T2DM are diagnosed each month? *

5-10

11-20

>20

In your clinical experience what proportion of T2DM patients are controlled (HBa1c ≤ 7%) *

<10%

10-<25%

25-50%

>50%

What proportion of your diabetic patients adhere to recommended lifestyle and dietary modifications? *

<10%

10-<25%

25-50%

>50%

What proportion of your diabetic patients have concomitant heart disease? *

<10%

10-<25%

25-50%

>50%

What percentage of your diabetic patients are obese? *

<10%

10-<25%

25-50%

>50%

How frequently do you recommend HBA1c test in your diabetic patients? *

3 monthly

6 monthly

12 monthly

Only if patient develops any complication

What is your approach in management of obese patients with T2D? (Please specify) *

How many antidiabetic agents/drugs are required by maximum number of your diabetic patients for adequate control? *

1 agent

2 agents

3 agents

≥3 agents and/or insulin

In your clinical practice which is the most common comorbidity associated with diabetes? *

Chronic Kidney Disease

Cardiovascular disease

Dyslipidemia

Obesity

Diabetic neuropathy

Diabetic retinopathy

Diabetic foot

Others

What is your opinion regarding the use of Sodium-glucose co-transporter-2 (SGLT-2) inhibitors? *

Must be preferred in all diabetic patients regardless of comorbidities

Must be preferred only in diabetic patients with heart failure or chronic kidney disease

Must be reserved for specific cases only

Not preferred due to risk of urinary tract infections and diabetic ketoacidosis

What is your opinion regarding the use of combination of Glimepiride + Metformin + Dapagliflozin? *

The combination must be preferred in all patients uncontrolled on dual therapy

I have a concern regarding day time hypoglycemia

I have a concern regarding blood sugar control at night

I have a concern regarding UTI and DKA

I prefer to use these agents separately due to concerns regarding titration

What benefits do you observe in your patients, when prescribed an FDC? (Please specify) *

In your opinion does is the triple combination Glimepiride + Metformin + Dapagliflozin effective in providing round the clock glycaemic control without any safety concerns? *

Yes

Can’t say

What is your opinion regarding continuous glucose monitoring and in which patient profiles will you prefer to use CGM? (Please specify) *

In which patient profiles do you recommend using continuous glucose monitoring? *

Must be advised to most diabetic patients who are uncontrolled

Must be advised to patients with very high and frequent glycemic fluctuations

Can be considered for elderly patients

Must be advised in patients taking multiple daily doses of insulin

Must be advised in only Type 1 Diabetes mellitus

In patients with HbA1c >8.5% what at the time of diagnosis what will be your preferred treatment initiation strategy? (Please specify) *

In patients >50 years not responding to 3 OHA drugs what is your preferred approach? *

Investigate for GAD antibodies

Investigate for C peptide levels

Start basal insulin

Adding 4^th OHA

In patient with UACR>300mg/g and HbA1c of >8 % which agents will you start? (Please specify) *

What is your primary concern while prescribing a triple drug combination in diabetes? *

Hypoglycemia

Cost

Titration of individual drugs

Do not have any concern

What is the most commonly observed complication in your diabetic patients? *

Diabetic Nephropathy

Diabetic Neuropathy

Diabetic foot

Diabetic retinopathy

Cardiovascular disease

What is your approach in management of older/elderly patients with T2D? (Please specify) *

What is your opinion on protein restriction in CKD patients with diabetes? *

Protein intake must be restricted to <0.8 gm/Kg

Do not recommend protein restriction in early stages of CKD

Do not recommend protein restriction at any stage of CKD

In your CKD patients with diabetes which agents do you prefer in the following classes? (Please specify) *

SGLT2i
ACE/ARB
MRA
GLP1RA

What is your approach in patients having brittle diabetes? (Please specify) *

As per the VERFIY trial, conventional approach of adding drugs in T2DM seems to be an inferior strategy as compared to therapy initiation with combination of drugs. Do you agree with this approach? If yes then why? (Please specify) *

Yes

What LDL goal do you target in you diabetic patients with multiple ASCVD risk factors? *

<130 mg/dl

<100 mg/dl

<70 mg/dl

<55 mg/dl

In your clinical experience additional drugs for escalation of therapy are required after how many years of initiation of therapy to control of glycemia? (Please specify) (The years to be counted from the initiation of first OAD) *

Addition of second OAD	Years
Addition of third OAD	Years
Addition of injectable drug	Years

Which is your sulfonylurea of choice in patients with mild to moderate renal insufficiency? *

Glibenclamide

Glipizide

Glimepiride

Tolubutamide

Kindly describe the major challenges in the treatment of elderly patients with diabetes and the most effective strategy for management?*